Cushing Syndrome clinical trials
The registry lists 123 studies for Cushing Syndrome across more than 10 countries. 42 are recruiting or about to start. 84 of them are mainly about Cushing Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.
Get an email when these change. Save the Cushing Syndrome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Corcept Therapeutics (16) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (9) · RECORDATI GROUP (5) · Haukeland University Hospital (5) · Mayo Clinic (4) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (4) · National Institute of Mental Health (NIMH) (3) · HRA Pharma (3)
What is being tested here
Drugs under test in Cushing Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest
- Nov 2026Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome · Peking Union Medical College Hospital
- Nov 2026Collecting Information About Treatment Results for Patients With Cushing's Syndrome · Memorial Sloan Kettering Cancer Center
- Dec 2026Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome · Corcept Therapeutics
- Dec 2026Automated Capture of Core Data for Rare Diseases and Glucocorticoid Complications: Biomarkers and Patient-Reported Outcomes · Assistance Publique - Hôpitaux de Paris
- Dec 2026A Single Center Randomized Controlled Study on the Promotion of Rapid Recovery · Zhe Meng
- Jan 2027Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS) · Mayo Clinic
- Jun 2027Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome · RECORDATI GROUP
- Jun 2027Salivary Cortisol and Hypercortisolism in Type 2 Diabetes · Shanghai 6th People's Hospital
- Jun 2027Establishment and Clinical Application of Reference Intervals of Salivary Cortisol · Shanghai 6th People's Hospital
- Jul 2027Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome · RECORDATI GROUP
Who these studies take
Of the 35 Cushing Syndrome studies recruiting now, 14 (40%) set no upper age limit and 10 (29%) stop at 75 or younger. 8 (23%) take children under 18. 0 (0%) are for women only and 1 (3%) for men only; 7 (20%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 6 (17%) | 6 (17%) |
| 18 | 32 (91%) | 33 (94%) |
| 30 | 32 (91%) | 33 (94%) |
| 40 | 31 (89%) | 32 (91%) |
| 50 | 31 (89%) | 32 (91%) |
| 65 | 31 (89%) | 32 (91%) |
| 75 | 28 (80%) | 29 (83%) |
| 85 | 17 (49%) | 17 (49%) |
Across all 123 studies, recruiting or not: 28% stop at 75 or younger and 10% at 65; 20% take children; 1% are for women only and 1% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Cushing Syndrome studies take
Of 31 observational studies under Cushing Syndrome, half reached primary completion within 95 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Observational | 95 mo85–… · 31 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting2
Newly registered2
- Relacorilant in Patients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol SecretionNov 9, 2026NCT07925801
- Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized, Double-Blind, Placebo-Controlled Phase 2 StudyNov 6, 2026NCT07922148
Studies
Recruiting first, then most recently updated. Showing 50 of 123. Browse all 123 → or search them.
- Relacorilant in Patients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol SecretionNot yet recruitingNCT07925801Phase 1/21 country
- Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized, Double-Blind, Placebo-Controlled Phase 2 StudyNot yet recruitingNCT07922148Phase 21 country
- Automated Capture of Core Data for Rare Diseases and Glucocorticoid Complications: Biomarkers and Patient-Reported OutcomesNot yet recruitingNCT079164151 country
- Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's SyndromeRecruitingNCT07350707Phase 1/21 country
- Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's SyndromeRecruitingNCT07247162Phase 41 country
- Collecting Information About Treatment Results for Patients With Cushing's SyndromeRecruitingNCT033648031 country
- Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and HypercortisolismRecruitingNCT06246357Phase 21 country
- Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid DisordersRecruitingNCT04374721Not applicable1 country
- Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)RecruitingNCT07296484Phase 21 country
- Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing SyndromeRecruitingNCT02019706Phase 21 country
- Evaluation of Adults With Endocrine and Metabolic-Related ConditionsRecruitingNCT028303081 country
- Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACSRecruitingNCT07138274Phase 21 country
- Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)RecruitingNCT045432531 country
- A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid ReplacementRecruitingNCT064305281 country
- Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing SyndromeRecruitingNCT06635629Phase 21 country
- Salivary Cortisol and Hypercortisolism in Type 2 DiabetesRecruitingNCT071563701 country
- Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine DiseasesRecruitingNCT077036831 country
- NAC- NAFLD And CushingRecruitingNCT05881005Not applicable1 country
- Endoscopic Ultrasound-guided Radiofrequency Ablation in Primary AldosteronismRecruitingNCT05368090Not applicable1 country
- Adrenal Tumors - Pathogenesis and TherapyRecruitingNCT006692661 country
- Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's SyndromeRecruitingNCT03708900Phase 27 countries
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol SecretionRecruitingNCT07361874Not applicable1 country
- REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)RecruitingNCT07412782Not applicable1 country
- Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)RecruitingNCT07104812Phase 21 country
- Institutional Registry of Rare DiseasesRecruitingNCT065737231 country
- Establishment and Clinical Application of Reference Intervals of Salivary CortisolRecruitingNCT071681221 country
- Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CTRecruitingNCT069622021 country
- Continuous Steroid Monitoring in Interstitial Fluid With Wearable and Nanoparticle-enhanced Biosensors for Improved Management of Adrenal DisordersNot yet recruitingNCT06980753Not applicable1 country
- Study of the Steroid Hormone Milieu in Obese PatientsRecruitingNCT063416991 country
- Cushing's Syndrome Before and After Treatment (CORRECT)RecruitingNCT055215291 country
- Impact of Adrenal IncidenTalomas and Possible Autonomous Cortisol Secretion on Cardiovascular and Metabolic AlterationsRecruitingNCT041275521 country
- Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's SyndromeRecruitingNCT06801249Phase 41 country
- Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma DetectionNot yet recruitingNCT06701838
- Dynamic Hormone Profiling and Multimodal Data Capture in Primary AldosteronismRecruitingNCT064959831 country
- Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical ModelsNot yet recruitingNCT06326853
- Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World DataRecruitingNCT062294051 country
- A Single Center Randomized Controlled Study on the Promotion of Rapid RecoveryRecruitingNCT06250699Not applicable1 country
- Evaluation of the Severity of Hepatic Fibrosis by Magnetic Resonance Elastography in the Diagnosis of Endogenous HypercorticismRecruitingNCT05911620Not applicable1 country
- Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted AdrenalectomyRecruitingNCT060500571 country
- Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological FluidsRecruitingNCT060081841 country
- China Adrenal Disease RegistryRecruitingNCT048904441 country
- A Prospective Cohort Study for Patients With Adrenal DiseasesEnrolling by invitationNCT034742371 country
- Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney ComplexCompletedNCT000014521 country
- Study of Adrenal Gland TumorsCompletedNCT000059271 country
- Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeActive, not recruitingNCT03604198Phase 210 countries
- A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's SyndromeCompletedNCT05804669Phase 1/21 country
- Metyrapone for Mild Autonomous Cortisol Secretion (MACS)Active, not recruitingNCT06106295Phase 21 country
- In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in ManCompletedNCT02889224Not applicable1 country
- Genomic and Metabolomic Markers Reflecting the Complications of Hypercortisolism (CUSHINGOMICS)Active, not recruitingNCT04840693Not applicable1 country
- Preclinical Study Towards an Immunotherapy in Adrenocortical CarcinomaActive, not recruitingNCT004575871 country